Avenue Therapeutics Inc.

Company Overview

Business Model: AVENUE THERAPEUTICS, INC. is a specialty pharmaceutical company focused on the development and commercialization of therapies for neurologic diseases. Its current product candidates are ATX-04, a selective β2-adrenergic agonist for Pompe disease, and intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain. The company previously developed AJ201 and BAER-101, which have since been divested, with future potential for contingent milestone and royalty payments from these assets. The company does not currently have any drug products approved for commercial sale.

Market Position: AVENUE THERAPEUTICS, INC. is a development-stage company with no commercialized products. Its business success is contingent on obtaining regulatory approval and successfully commercializing ATX-04 and IV tramadol. If approved, IV tramadol would be the only intravenous Schedule IV opioid on the market, potentially offering a competitive advantage due to less stringent regulatory requirements compared to Schedule II opioids. ATX-04 is being developed as an adjunct to existing enzyme replacement therapies (ERTs) for Pompe disease. The company operates in a highly competitive industry against larger pharmaceutical and biotechnology companies with significantly greater resources.

Recent Strategic Developments:

• ATX-04 License Agreement (February 2026): AVENUE THERAPEUTICS, INC. entered into an exclusive worldwide license agreement with Duke University for patents and know-how related to clenbuterol (ATX-04) for lysosomal storage diseases, with an initial focus on Pompe disease. The agreement included an upfront payment, reimbursement of patent expenses, and obligations for future development, regulatory, and commercial milestone payments, plus tiered low single-digit royalties on net sales.
• AJ201 License Termination (April 2025): The exclusive license agreement with AnnJi Pharmaceutical Co. Ltd. for AJ201 was terminated. AVENUE THERAPEUTICS, INC. transferred all rights to AJ201 back to AnnJi Pharmaceutical Co. Ltd., repurchased shares held by AnnJi Pharmaceutical Co. Ltd. for $1.00, and paid $0.2 million for legal expenses. AVENUE THERAPEUTICS, INC. is eligible to receive up to $5 million in development milestones, up to $17 million in regulatory milestones, a 1.75% royalty on net sales, and a percentage of sublicensing revenue from AnnJi Pharmaceutical Co. Ltd.
• BAER-101 Sale (November 2025): AVENUE THERAPEUTICS, INC. sold its majority-controlled subsidiary, Baergic Bio, Inc., including global rights to BAER-101 (now AXS-17), to Axsome Therapeutics, Inc. for an upfront payment of $0.3 million (less transaction fees) and additional contingent consideration. AVENUE THERAPEUTICS, INC. is eligible to receive approximately 74% of future payments, including up to $2.5 million in development milestones, up to $79 million in regulatory and sales milestones, and a tiered mid-to-high single-digit royalty on net sales.
• IV Tramadol Regulatory Progress: In January 2024, AVENUE THERAPEUTICS, INC. reached final agreement with the FDA on the Phase 3 safety study protocol and statistical analysis approach for IV tramadol. The non-inferiority study will assess the risk of opioid-induced respiratory depression compared to IV morphine. Initiation of this study is contingent on obtaining necessary financing or partnership.
• Nasdaq Delisting (March/July 2025): AVENUE THERAPEUTICS, INC.'s common stock was delisted from The Nasdaq Capital Market due to non-compliance with listing rules and now trades on the OTC Pink Open Market under the symbol "ATXI."

Geographic Footprint: AVENUE THERAPEUTICS, INC.'s primary focus for product development and potential commercialization is the United States. The ATX-04 license is worldwide. The IV tramadol license is exclusive in the United States, with specific exceptions for Canada, Central America, and South America regarding 50 mg and 100 mg IV tramadol HCl injections. The non-compete agreement for AJ201 covers the US, Canada, the European Union, Great Britain, and Israel.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (development-stage company with no product sales).
• Operating Margin: Not applicable (operating at a loss).
• Net Margin: Not applicable (operating at a loss).

Investment in Growth:

• R&D Expenditure: $1.037 million (74.1% of total revenue) in 2025, a decrease of 84.4% from $6.645 million in 2024.
• Capital Expenditures: Not explicitly disclosed as a separate line item.
• Strategic Investments: An upfront payment and patent expense reimbursement were made to Duke University for the ATX-04 license (specific amounts not detailed in 2025 financials).

Business Segment Analysis

AVENUE THERAPEUTICS, INC. operates in one reportable segment: development and commercialization of therapies for the treatment of neurologic diseases. The following details pertain to its primary product candidates.

ATX-04

Financial Performance:

• Revenue: Not yet generating revenue.
• Operating Margin: Not applicable (in development).
• Key Growth Drivers: AVENUE THERAPEUTICS, INC. holds an exclusive worldwide license for ATX-04 (clenbuterol) for lysosomal storage diseases, with an initial focus on Pompe disease as an adjunct to enzyme replacement therapy (ERT). A 52-week Phase I/II clinical study at Duke University demonstrated meaningful improvements in functional capacity, respiratory muscle strength, reductions in muscle glycogen burden, increased GAA activity, and broad normalization of disease-relevant gene expression in Pompe disease patients on baseline ERT. The therapy was generally well tolerated. AVENUE THERAPEUTICS, INC. is preparing for a pre-IND meeting with the FDA to discuss a pivotal study design.

Product Portfolio:

• ATX-04 (clenbuterol): An investigational, orally administered, selective β2-adrenergic agonist.
• Initial focus: Pompe disease as an adjunct to ERT, with potential for expansion into other related indications.

Market Dynamics:

• Pompe disease is a rare, inherited lysosomal storage disorder affecting approximately 25,000 to 35,000 patients across the United States and Europe, believed to be underdiagnosed.
• ATX-04 is expected to be used in combination with existing approved ERTs (e.g., Myozyme/Lumizyme (Sanofi), Nexviazyme (Sanofi)).
• Competition includes an approved combination therapy, Pombiliti/Opfolda (Amicus), and investigational therapies such as gene therapies, mRNA therapies, substrate reduction therapies, and gene editing approaches. No approved therapies are known to specifically increase cellular uptake of ERTs in muscle tissue.

IV Tramadol

Financial Performance:

• Revenue: Not yet generating revenue.
• Operating Margin: Not applicable (in development).
• Key Growth Drivers: AVENUE THERAPEUTICS, INC. has an exclusive license with Revogenex to develop and commercialize IV tramadol in the United States. The company reached final agreement with the FDA in January 2024 on the Phase 3 safety study protocol and statistical analysis approach. This non-inferiority study will assess the risk of opioid-induced respiratory depression compared to IV morphine in approximately 300 post-bunionectomy patients. Prior Phase 3 efficacy trials in bunionectomy and abdominoplasty met their primary and key secondary endpoints.

Product Portfolio:

• IV tramadol: A synthetic dual-acting opioid, centrally acting analgesic with weak opioid agonist properties, also inhibiting serotonin and noradrenaline re-uptake.
• Classified as a Schedule IV controlled substance, which has a lower potential for abuse and dependence compared to Schedule II opioids.
• Patent protection covers specific methods of intravenous administration (e.g., 10-45 minutes, 15±2 minutes infusion) and dosing regimens (e.g., 50 mg every 4 hours after initial loading doses), with patents expiring between October 20, 2032, and April 13, 2037, absent extensions.

Market Dynamics:

• The postoperative pain market is characterized by established, low-cost generic pain relievers, but AVENUE THERAPEUTICS, INC. believes there is an unmet need for safer and better-tolerated analgesics.
• Competitors include various IV narcotics (e.g., morphine, hydromorphone, fentanyl, OLINVYK (oliceridine), Journavx (suzetrigine)), IV NSAIDs (e.g., Dyloject (diclofenac), Toradol (ketorolac)), IV acetaminophen (Ofirmev), and local anesthetics (e.g., Exparel (bupivacaine liposome injectable suspension)).
• Public concern regarding opioid safety and legislative efforts to reduce opioid use could negatively impact market acceptance and regulatory pathways.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Repurchased 14,777 shares of common stock from AnnJi Pharmaceutical Co. Ltd. for an aggregate payment of $1.00 in April 2025.
• Dividend Payments: AVENUE THERAPEUTICS, INC. has never paid or declared any cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain all available funds for business development.
• Future Capital Return Commitments: No explicit future capital return commitments beyond the AnnJi Pharmaceutical Co. Ltd. transaction.

Balance Sheet Position:

• Cash and Equivalents: $2.855 million as of December 31, 2025.
• Total Debt: No significant long-term debt disclosed. Current liabilities include $0.468 million in accounts payable and accrued expenses and $0.630 million in related party accounts payable and accrued expenses.
• Net Cash Position: $2.855 million (assuming no significant long-term debt).
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable (no significant debt).

Cash Flow Generation:

• Operating Cash Flow: $(1.833) million for the year ended December 31, 2025.
• Free Cash Flow: Not explicitly stated, but negative given operating losses and minimal capital expenditures.
• Cash Conversion Metrics: Not applicable (development-stage company with no product sales).

Operational Excellence

Production & Service Model:

• AVENUE THERAPEUTICS, INC. does not own or operate manufacturing facilities. It relies entirely on third-party contract development and manufacturing organizations (CDMOs) for raw materials, drug substance, drug product, and packaging for its product candidates.
• Polpharma is the current CDMO for clinical and commercial supply of IV tramadol, with some activities subcontracted. AVENUE THERAPEUTICS, INC. is obligated to purchase a minimum amount of final packaged drug product from this manufacturer post-approval.
• AVENUE THERAPEUTICS, INC. is in the process of establishing supply and manufacturing sources for ATX-04 and expects to engage a CDMO.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing: Polpharma (for IV tramadol).
• Licensors: Revogenex (for IV tramadol), Duke University (for ATX-04).
• Clinical Research: Relies on third-party contract research organizations (CROs) and clinical research organizations for preclinical studies and clinical trials.

Facility Network:

• Corporate & Executive Office: 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 (provided by Fortress Biotech, Inc. at no cost).
• Manufacturing: Relies on third-party facilities.
• Research & Development: Relies on third-party facilities and collaborators.
• Distribution: Expects to rely on third parties for drug supply storage and distribution.

Operational Metrics:

• Specific operational metrics such as capacity utilization, efficiency measures, or quality indicators are not explicitly disclosed, consistent with a development-stage company relying on third-party manufacturers.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: AVENUE THERAPEUTICS, INC. plans to build its own marketing and sales organization or enter into agreements with third-party contract organizations to perform these services if product candidates receive marketing approval.
• Channel Partners: May partner with third parties that have established direct sales forces.
• Digital Platforms: Not explicitly mentioned.

Customer Portfolio: Enterprise Customers:

• Not applicable as no products are currently approved for commercial sale. Future customers would include healthcare providers, physicians, hospitals, and third-party payors.
• Customer Concentration: Not applicable.

Geographic Revenue Distribution:

• Not applicable as no product-related revenue has been generated. Future revenue focus is primarily the United States for IV tramadol, while ATX-04 has worldwide rights.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. There is a significant unmet medical need for safer and better-tolerated analgesics in the postoperative pain market. Pompe disease is a rare, inherited lysosomal storage disorder with an estimated prevalence of 1 in 20,000 to 1 in 30,000 individuals.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• For IV Tramadol (postoperative pain):
  • Opioid Agonists: Morphine, hydromorphone, fentanyl, OLINVYK (oliceridine), Journavx (suzetrigine).
  • Non-Opioid Analgesics: Combogesic (combination IV acetaminophen and ibuprofen), Ofirmev (IV acetaminophen), and IV formulations of NSAIDs such as Dyloject (diclofenac), Toradol (ketorolac), Anjeso (meloxicam), and Caldolor (ibuprofen).
  • Local Anesthetics: Exparel (bupivacaine liposome injectable suspension), Zynrelef (bupivacaine and meloxicam), and Xaracoll (bupivacaine implant).
  • Product Candidates in Development: LTG-001 (Latigo Biotherapeutics), LY4515100 (Eli Lilly), Halneuron Nav1.7 (Dogwood Therapeutics), and CA-008 (Concentric Analgesics).
• For ATX-04 (Pompe disease):
  • Existing ERTs: Myozyme/Lumizyme (Sanofi) and Nexviazyme (Sanofi).
  • Approved Combination Therapy: Pombiliti/Opfolda (Amicus).
  • Investigational Therapies: Muscle and liver-targeted adeno-associated viral vector gene therapy approaches, mRNA therapies, substrate reduction therapies, and gene editing approaches.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in pain management and rare disease treatment. Public concern and legislative efforts to reduce opioid use could significantly impact IV tramadol's market.

Competitive Response Strategy: AVENUE THERAPEUTICS, INC.'s strategy focuses on obtaining FDA approval for IV tramadol and advancing ATX-04 through late-stage clinical development. It aims to leverage IV tramadol's Schedule IV classification and unique administration/dosing profile as competitive differentiators. For ATX-04, the strategy is to position it as a mechanistic potentiator of ERT. The company also seeks to maintain, expand, protect, and monetize its intellectual property.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Product Pipeline Limitation: The termination of the AJ201 license and the sale of BAER-101 have narrowed AVENUE THERAPEUTICS, INC.'s product pipeline to ATX-04 and IV tramadol, increasing the company's dependence on their successful development and commercialization.
• Competition: AVENUE THERAPEUTICS, INC. faces intense competition from larger, more resourced pharmaceutical and biotechnology companies, which may achieve regulatory approvals more rapidly or develop superior/lower-cost alternatives.
• Opioid Safety Concerns: Widespread public, medical, and governmental concerns regarding opioid safety could delay or prevent regulatory approval for IV tramadol, lead to more restrictive labeling, negatively impact market performance, or necessitate costly risk management programs.
• Regulatory Delays/Failure: There is a significant risk of delays or failure to obtain regulatory approval for ATX-04 and IV tramadol due to scientific, safety, or regulatory reasons, as evidenced by IV tramadol's prior Complete Response Letters and an unfavorable Advisory Committee vote.
• Market Acceptance: Commercial success is uncertain and depends on acceptance by the medical community, inclusion in hospital formularies, and adequate coverage and reimbursement by third-party payors.
• Pricing & Reimbursement: Unfavorable pricing regulations, third-party coverage decisions, and healthcare reform initiatives (e.g., the Inflation Reduction Act of 2022, "One Big Beautiful Bill Act") could limit potential revenue and profitability.
• Technology Disruption: Rapid technological advancements in the pharmaceutical industry could render AVENUE THERAPEUTICS, INC.'s product candidates obsolete or noncompetitive.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on a single third-party CDMO (Polpharma for IV tramadol) increases the risk of supply disruptions, quality control issues, or non-compliance with current Good Manufacturing Practice (CGMP) requirements.
• Capacity Constraints: Potential for manufacturing delays or inability to meet market demand if CDMOs fail to deliver sufficient quantities on a timely basis or at acceptable cost and quality.
• Third-Party Reliance for Clinical Trials: Dependence on third-party contract research organizations (CROs) and clinical research organizations for preclinical studies and clinical trials reduces direct control over these activities and introduces risks of unsatisfactory performance, missed deadlines, or non-compliance with regulatory requirements (e.g., Good Clinical Practices).

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Doubt: There is substantial doubt about AVENUE THERAPEUTICS, INC.'s ability to continue as a going concern due to significant accumulated losses ($105.5 million as of December 31, 2025) and the expectation of continued operating losses for the foreseeable future.
• Funding Needs: The company requires substantial additional funding to advance its product candidates and potential commercialization efforts. There is no assurance that such funding will be available on acceptable terms, or at all, which could lead to delays, scaling back, or discontinuation of development programs.
• Dilution: Future capital raises through equity or convertible debt financings could result in significant dilution to existing stockholders.
• Nasdaq Delisting: The delisting of common stock from Nasdaq and its trading on the OTC Pink Open Market adversely affects liquidity, market price, and the company's ability to raise additional capital.
• Product Liability: The use of product candidates in clinical trials and potential commercial sales exposes the company to product liability claims, with limited current insurance coverage that may not be sufficient to cover substantial liabilities.

Regulatory & Compliance Risks:

• DEA Rescheduling: The DEA could reclassify tramadol from a Schedule IV to a more restrictive Schedule (II or III), which would substantially increase the regulatory burden, impact IV tramadol's competitive advantage, and potentially delay or prevent approval.
• Off-Label Promotion: Strict regulations on post-approval marketing and promotion limit the company to approved indications. Non-compliance with these requirements could lead to enforcement actions, fines, and reputational damage.
• Healthcare Laws: AVENUE THERAPEUTICS, INC. is subject to various federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA), which could expose it to criminal sanctions, civil penalties, and reputational harm for non-compliance.
• Government Policy Changes: Shifts in U.S. government policy, regulation, and enforcement priorities (e.g., FDA, drug pricing, healthcare reform) are uncertain and could materially and adversely affect the company's business, financial condition, and results of operations.

Geopolitical & External Risks

Geopolitical Exposure:

• Global Economic Conditions: Unfavorable global economic, political, and market conditions, including geopolitical conflicts, trade restrictions, tariffs, and inflationary pressures, could materially negatively affect AVENUE THERAPEUTICS, INC.'s operations and liquidity.
• Cybersecurity: Increased reliance on information technology systems and data exposes the company to risks of system failures, cyber-attacks, or data breaches, potentially leading to operational disruptions, data loss, legal liability, and reputational harm.
• Catastrophic Disasters: The company is vulnerable to damage and/or loss of vital data from natural disasters or other catastrophic events, which could seriously impair business operations, potentially beyond insurance limits.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• ATX-04: Focuses on a selective β2-adrenergic agonist (clenbuterol) for lysosomal storage diseases, particularly Pompe disease. The technology aims to increase the expression or availability of cell-surface receptors involved in lysosomal enzyme uptake, serving as a mechanistic potentiator of ERT.
• IV Tramadol: Focuses on a synthetic dual-acting opioid that acts as a centrally acting analgesic with weak opioid agonist properties and inhibits serotonin and noradrenaline re-uptake. R&D is centered on specific intravenous administration methods and dosing regimens designed to optimize efficacy, tolerability, and transition from IV to oral therapy for post-operative acute pain.

Innovation Pipeline:

• ATX-04: Currently preparing for a pre-IND meeting with the FDA to align on a pivotal study design for Pompe disease.
• IV Tramadol: Final agreement reached with the FDA in January 2024 on the Phase 3 safety study protocol and statistical analysis approach, with study initiation contingent on financing or partnership.

Intellectual Property Portfolio:

• Patent Strategy: AVENUE THERAPEUTICS, INC. aims to obtain, maintain, and enforce patent protection for its proprietary technologies, including methods of treatment, and to preserve trade secrets.
• Patent Holdings (IV Tramadol): Holds exclusive commercialization rights to numerous U.S. patents related to "Intravenous Administration of tramadol." These patents cover methods of treating pain by administering IV tramadol over specific time periods (e.g., 10-45 minutes, 15±2 minutes), specific doses (e.g., 50 mg, 25 mg, 60 mg), pharmacokinetic properties (e.g., Cmax, AUC), and dosing regimens (e.g., 50 mg every 4 hours after initial loading doses). Key patents are scheduled to expire between October 20, 2032, and April 13, 2037, absent possible regulatory patent term extensions. Patents also cover co-administration with other analgesics.
• Patent Holdings (ATX-04): Holds exclusive worldwide rights to U.S. Patent No. 8,679,478, titled "Methods of Lysosomal Storage Disease Therapy," which generally covers methods for improving the treatment of lysosomal storage diseases through the administration of a lysosomal enzyme therapy in combination with a second therapeutic agent, including β-adrenergic agonists like clenbuterol. This patent is expected to expire in 2031. Rights to a U.S. provisional application, if issued, would be expected to expire in 2046.
• Trade Secret Protection: Relies on trade secrets, including unpatented know-how and proprietary information, protected through non-disclosure and confidentiality agreements with employees, licensors, collaborators, and contractors.
• Orphan Drug Designation: May utilize orphan drug regulations to provide market exclusivity for certain product candidates, such as ATX-04 for Pompe disease.

Technology Partnerships:

• Strategic Alliances: Duke University (for ATX-04 license and prior clinical study), Revogenex (for IV tramadol license).
• Research Collaborations: Not explicitly detailed beyond the Duke University collaboration.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: AVENUE THERAPEUTICS, INC. is a majority-controlled subsidiary of Fortress Biotech, Inc. Some executive officers and directors also serve in similar roles at Fortress Biotech, Inc. or its affiliates, which may create potential conflicts of interest. The Board does not have a formal policy regarding the separation of the Chief Executive Officer and Chairman roles.

Board Composition: The Board of Directors consists of six members: Jay Kranzler, M.D., PhD (Chairman), Faith Charles, Neil Herskowitz, Lindsay A. Rosenwald, M.D., Curtis Oltmans, and Alexandra MacLean, M.D.

• Audit Committee: Composed of Neil Herskowitz (Chairperson), Curtis Oltmans, and Faith Charles. All members are deemed independent, and Mr. Herskowitz is designated as an "audit committee financial expert."
• Compensation Committee: Composed of Neil Herskowitz (Chairperson) and Curtis Oltmans. All members are deemed independent.
• Nominating Process: AVENUE THERAPEUTICS, INC. does not have a dedicated nominating committee. Director nominations are approved by a majority vote of the independent directors, and the Board considers candidates recommended by stockholders.

Human Capital Strategy

Workforce Composition:

• Total Employees: 1 full-time employee as of December 31, 2025.
• Geographic Distribution: Not explicitly detailed.
• Skill Mix: Not explicitly detailed, but the company relies on a number of expert advisors and consultants.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Not explicitly detailed.
• Retention Metrics: Not disclosed.
• Employee Value Proposition: Not explicitly detailed.

Diversity & Development:

• Diversity Metrics: Not disclosed.
• Development Programs: Not disclosed.
• Culture & Engagement: Not disclosed.

Environmental & Social Impact

Environmental Commitments: AVENUE THERAPEUTICS, INC. is subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. The company contracts with third parties for the disposal of these materials. No specific emissions targets, carbon neutrality commitments, or renewable energy strategies are disclosed.

Supply Chain Sustainability: Not explicitly detailed.

Social Impact Initiatives: Not explicitly detailed.